Welcome to our dedicated page for NAYA Biosciences SEC filings (Ticker: NAYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NAYA SEC filings archive on Stock Titan documents the regulatory history associated with the period when the public company operated under the NAYA Biosciences, Inc. name and ticker, and then transitioned to INVO Fertility, Inc. with the IVF symbol. Later Form 8‑K reports identify the registrant as INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., and show that the company is incorporated in Nevada and files under Commission File Number 001‑39701.
Within these filings, investors can review disclosures on corporate actions that affected capital structure and trading, such as reverse stock splits, amendments to articles of incorporation, and changes to authorized share counts. Several 8‑K filings describe reverse stock splits, associated CUSIP changes, and the continued listing of the company’s common stock on The Nasdaq Capital Market, along with the transition of the trading symbol from NAYA to IVF.
The filings also provide detail on financing arrangements and preferred equity structures. For example, multiple 8‑Ks discuss the Series C‑2 Non‑Voting Convertible Preferred Stock, amendments to its certificate of designation, additional investment rights granted to an institutional holder, exchanges between preferred shares and a senior secured convertible debenture, and related adjustments to conversion prices. Other filings describe unregistered sales of equity securities relying on exemptions under Sections 3(a)(9) and 4(a)(2) of the Securities Act and Rule 506.
Additional 8‑K reports cover matters such as changes in the independent registered public accounting firm, going‑concern language in prior audit reports, and the engagement of a new auditor. Stockholder meeting results, including votes on director elections, approval of conversion proposals for the Series C‑2 preferred stock and a senior secured convertible debenture, warrant‑related proposals, stock incentive plan amendments, and advisory votes on executive compensation, are also summarized in these documents.
On Stock Titan, these SEC filings are updated from EDGAR in near real time and are paired with AI‑generated highlights to help readers quickly identify key items, such as reverse stock split terms, preferred stock features, or material financing agreements. Users can also locate insider‑related information where reported on Form 4 and access the company’s periodic reports, including 10‑K and 10‑Q filings, to see how NAYA‑era and INVO Fertility disclosures describe the evolution from a life science portfolio company to a fertility‑focused healthcare services business.
NAYA Biosciences, Inc. has submitted a Schedule 14A – Definitive Additional Materials (Form DEFA14A) with the U.S. Securities and Exchange Commission. The filing indicates that the company, listed in the document under the legal name INVO Fertility, Inc., is providing supplemental proxy solicitation materials rather than a full definitive proxy statement. According to the cover page, the materials are filed by the registrant and no filing fee is required for this submission. No financial data, transaction details, or voting proposals are included in the excerpt provided.